[Treatment of cardiac arrhythmias with N-propyl-ajmalinium-hydrogentartrat (Neo-Gilurytmal (author's transl)].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000404:Ajmaline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy; D013644:Tartrates / Q000627:therapeutic use*; D014693:Ventricular Fibrillation / Q000188:drug therapy; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D000644:Quaternary Ammonium Compounds; D013644:Tartrates; D000404:Ajmaline
Behandlung von Herzrhythmusstörungen mit N-Propyl-ajmalinium-hydrogentartrat (Neo-Gilurytmal)